Tenalisib
Sponsors
Rhizen Pharmaceuticals SA
Conditions
Classical Hodgkin LymphomaHematological MalignanciesLeukemia, Lymphocytic, Chronic, B-CellPeripheral T Cell LymphomaT Cell LymphomaTriple Negative Breast Cancer (TNBC)
Phase 1
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
TerminatedNCT03471351
Start: 2018-07-18End: 2019-02-13Updated: 2019-12-27
Compassionate Use Study of Tenalisib (RP6530)
CompletedNCT03711604
Start: 2018-11-28End: 2023-03-25Updated: 2024-05-08
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
CompletedNCT03770000
Start: 2019-03-12End: 2021-05-14Updated: 2022-10-28
Phase 2
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
CompletedNCT04204057
Start: 2019-11-28End: 2020-10-02Updated: 2024-08-13
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
WithdrawnNCT05239910
Start: 2023-01-31End: 2027-05-31Updated: 2022-10-17
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
RecruitingNCT06189209
Start: 2024-03-04End: 2027-03-31Target: 40Updated: 2025-12-02